Cargando…

Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy

Clozapine is an atypical antipsychotic used in the treatment of refractory schizophrenia. It has a well-known side effect profile, including agranulocytosis, decreased seizure threshold, and tardive dyskinesia. In addition, numerous case reports have described clozapine-induced stuttering in adults....

Descripción completa

Detalles Bibliográficos
Autores principales: Rachamallu, Vivekananda, Haq, Ayman, Song, Michael M., Aligeti, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556608/
https://www.ncbi.nlm.nih.gov/pubmed/28835863
http://dx.doi.org/10.1155/2017/7359095
_version_ 1783257096176795648
author Rachamallu, Vivekananda
Haq, Ayman
Song, Michael M.
Aligeti, Manish
author_facet Rachamallu, Vivekananda
Haq, Ayman
Song, Michael M.
Aligeti, Manish
author_sort Rachamallu, Vivekananda
collection PubMed
description Clozapine is an atypical antipsychotic used in the treatment of refractory schizophrenia. It has a well-known side effect profile, including agranulocytosis, decreased seizure threshold, and tardive dyskinesia. In addition, numerous case reports have described clozapine-induced stuttering in adults. However, there has been only one previous case report describing it in the adolescent population. In addition, concurrent lithium therapy has been shown to enhance the neurotoxic effects of antipsychotics and lower the seizure threshold. Here, we report on the development of clozapine-induced microseizures, orofacial dyskinesia, and stuttering in a 17-year-old adolescent male with treatment of refractory early onset schizophrenia on clozapine and concurrent lithium therapy. The patient's symptoms of schizophrenia responded well to the clozapine regimen. However, with the escalating dose of clozapine, the patient developed speech dysfluency in the form of stuttering and perioral twitching. An electroencephalogram confirmed seizure activity. Due to similarities with tardive dyskinesia, symptoms of microseizures induced by atypical antipsychotics may not be accurately diagnosed. A multidisciplinary treatment of speech dysfluency is of particular importance in the adolescent schizophrenic patients, who are expected to have longer duration of lifetime exposure to antipsychotics and in whom peer group interaction is crucial for normal personal and social development.
format Online
Article
Text
id pubmed-5556608
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-55566082017-08-23 Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy Rachamallu, Vivekananda Haq, Ayman Song, Michael M. Aligeti, Manish Case Rep Psychiatry Case Report Clozapine is an atypical antipsychotic used in the treatment of refractory schizophrenia. It has a well-known side effect profile, including agranulocytosis, decreased seizure threshold, and tardive dyskinesia. In addition, numerous case reports have described clozapine-induced stuttering in adults. However, there has been only one previous case report describing it in the adolescent population. In addition, concurrent lithium therapy has been shown to enhance the neurotoxic effects of antipsychotics and lower the seizure threshold. Here, we report on the development of clozapine-induced microseizures, orofacial dyskinesia, and stuttering in a 17-year-old adolescent male with treatment of refractory early onset schizophrenia on clozapine and concurrent lithium therapy. The patient's symptoms of schizophrenia responded well to the clozapine regimen. However, with the escalating dose of clozapine, the patient developed speech dysfluency in the form of stuttering and perioral twitching. An electroencephalogram confirmed seizure activity. Due to similarities with tardive dyskinesia, symptoms of microseizures induced by atypical antipsychotics may not be accurately diagnosed. A multidisciplinary treatment of speech dysfluency is of particular importance in the adolescent schizophrenic patients, who are expected to have longer duration of lifetime exposure to antipsychotics and in whom peer group interaction is crucial for normal personal and social development. Hindawi 2017 2017-08-01 /pmc/articles/PMC5556608/ /pubmed/28835863 http://dx.doi.org/10.1155/2017/7359095 Text en Copyright © 2017 Vivekananda Rachamallu et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Rachamallu, Vivekananda
Haq, Ayman
Song, Michael M.
Aligeti, Manish
Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy
title Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy
title_full Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy
title_fullStr Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy
title_full_unstemmed Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy
title_short Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy
title_sort clozapine-induced microseizures, orofacial dyskinesia, and speech dysfluency in an adolescent with treatment resistant early onset schizophrenia on concurrent lithium therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556608/
https://www.ncbi.nlm.nih.gov/pubmed/28835863
http://dx.doi.org/10.1155/2017/7359095
work_keys_str_mv AT rachamalluvivekananda clozapineinducedmicroseizuresorofacialdyskinesiaandspeechdysfluencyinanadolescentwithtreatmentresistantearlyonsetschizophreniaonconcurrentlithiumtherapy
AT haqayman clozapineinducedmicroseizuresorofacialdyskinesiaandspeechdysfluencyinanadolescentwithtreatmentresistantearlyonsetschizophreniaonconcurrentlithiumtherapy
AT songmichaelm clozapineinducedmicroseizuresorofacialdyskinesiaandspeechdysfluencyinanadolescentwithtreatmentresistantearlyonsetschizophreniaonconcurrentlithiumtherapy
AT aligetimanish clozapineinducedmicroseizuresorofacialdyskinesiaandspeechdysfluencyinanadolescentwithtreatmentresistantearlyonsetschizophreniaonconcurrentlithiumtherapy